Navigation Links
Omeros Reports Additional Positive Results from OMS824 Program
Date:9/12/2013

evel is scheduled to be evaluated in the ongoing PET trial and is expected to demonstrate substantially higher target engagement. The Phase 1 clinical trial results predict that OMS824, at well-tolerated doses, will effectively inhibit PDE10 and support continuing development for the treatment of Huntington's disease, schizophrenia and other central nervous system disorders.

"These findings are unprecedented based on our knowledge of the work to date in the area of PDE10 inhibition and could result in a significant competitive advantage across a range of CNS indications," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "With this further confirmation of the unique pharmacology of our PDE10 inhibitor, Omeros is well positioned to initiate Phase 2 programs in schizophrenia and Huntington's disease before year-end."

About Omeros' PDE10 Program
PDE10 is an enzyme that is expressed in areas of the brain linked to diseases that affect cognition and psychomotor functions, including Huntington's disease and schizophrenia. Huntington's disease is a hereditary neurodegenerative disorder that leads to movement, cognition, and behavioral abnormalities and premature death. Schizophrenia is a group of severe brain disorders characterized by an abnormal interpretation of reality, which can manifest as delusions, hallucinations, and/or disordered thinking and behavior. Cognitive dysfunction is responsible for substantial disability in both of these diseases and is not meaningfully improved by current medications. Omeros' proprietary compound OMS824 inhibits PDE10 and is being developed for the treatment of cognitive disorders. In addition to potential benefits on cognition, OMS824 could also improve the motor and psychiatric abnormalities in Huntington's disease as well as the positive (e.g., hallucinations) and negative (e.g., flat affect) symptoms of schizophrenia.

About Omeros Corporation'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
2. Omeros to Present at the Stifel Healthcare Conference 2013
3. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
4. Omeros Corporation Reports Second Quarter 2013 Financial Results
5. Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
6. Omeros Submits New Drug Application to U.S. FDA for OMS302
7. Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
8. Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program
9. Omeros Corporation Reports First Quarter 2013 Financial Results
10. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
11. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , Oct. 31, 2014  Zacks.com announces the list of stocks ... analysts discuss the latest news and events impacting stocks and the ... AMGN - Free Report ), Celgene (Nasdaq: ... BIIB - Free Report ), Market Vectors Biotech ETF ... S&P Biotech ETF (AMEX: XBI - Free Report ...
(Date:10/31/2014)... , Oct. 31, 2014 /CNW Telbec/ - ... with its strategic plan, for accelerated growth in terms ... 32.6% and revenues reached $17,862,341. Net income amounted to ... threshold for the first time in the Company,s history. ... the Company joined the forces of its subsidiaries, merging ...
(Date:10/31/2014)... 2014 Though therapies are in their nascent ... show an annual increase of 16.2% over the 2010-2020 ... billion, according to Kalorama Information,s report, Stem Cell ... therapeutics that have gained or are expected to gain ... developers tackle ever more complicated conditions, stem cell therapies ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 2Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 3Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 4Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 5Report: Stem Cell Technologies Market Growing 2
(Date:10/31/2014)... 31, 2014 Fundraising support for fighting cancer ... than losses. At noon on Monday, November 10 in the ... (SSMH), greater than 20 Susquehanna Health (SH) employees and community ... awareness and funds for the new Cancer Center at SSMH. ... for this act of love and support to which many ...
(Date:10/31/2014)... first study of its kind, Rice University researchers have ... cause cancer cells to become metastatic. The research reveals ... cells to both migrate and form new tumors. Researchers ... drugs that interfere with the genetic switches that cancer ... circulating tumor cells -- two of the main players ...
(Date:10/31/2014)... October 31, 2014 The Memory Healer review ... by Alexander Lynch, whose father suffered from Alzheimer's disease. ... moment, caused by his father's disease. His father pointed a ... the crucial moment when the author of this method understood ... , The Memory Healer program is based on years ...
(Date:10/31/2014)... CA (PRWEB) October 31, 2014 ... also has amazing health effects for practitioners. ... by a Doctor of Science and Movement specializing ... his dedication to pelvic floor reeducation that traditional ... urinary incontinence, Diastasis Recti, Prolepses, etc. , The ...
(Date:10/31/2014)... Lake City, UT (PRWEB) October 31, 2014 ... announce the new Activz Silver line offering ... and cleansing wipes. For over a century, silver has ... formula found in Activz Silver products is the most ... U.S. patents, has a unique chemical structure that supports ...
Breaking Medicine News(10 mins):Health News:Susquehanna Health Soldiers + Sailors Memorial Hospital Razing Heads to Fight Cancer 2Health News:Decoding the emergence of metastatic cancer stem cells 2Health News:Decoding the emergence of metastatic cancer stem cells 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4
... News) -- Heart disease patients with high blood pressure ... drugs (NSAIDs) are at greater risk for heart attack, ... NSAIDS include popular medications such as such as aspirin, ... are published in the July issue of The ...
... Gordon HealthDay Reporter , THURSDAY, July 14 (HealthDay News) ... you probably memorized a lot more information -- such as phone ... a new study has found that the brain just doesn,t remember ... been saved on a computer. What people may remember, however, is ...
... transplant survival more than doubled in recent years for ... Research Hospital, with patients who lacked genetically matched donors ... to be the best ever reported for leukemia patients ... expected to make transplantation a treatment option for more ...
... can be admirable or romantic. In a cancerous tumor, it ... cells that have strayed from their original location to insinuate their ... way of determining whether a newly formed tumor is more likely ... the body. In a study published in the July 12 ...
... percent of patients with primary or metastatic cancer ... seizures, confusion, difficulty swallowing and visual disturbances. These ... brain invasion from cancer called neoplastic meningitis. Santosh ... San Diego School of Medicine and colleagues have ...
... 14 (HealthDay News) -- New research suggests that training ... other people could help them overcome anxiety and prevent ... Oxford University in the United Kingdom found that training ... negative interpretations of unclear social situations could influence how ...
Cached Medicine News:Health News:Certain Painkillers May Raise Odds of Stroke, Heart Attack: Study 2Health News: Can You Google Your Memory? 2Health News: Can You Google Your Memory? 3Health News: Can You Google Your Memory? 4Health News:Bone marrow transplant survival more than doubles for young high-risk leukemia patients 2Health News:Bone marrow transplant survival more than doubles for young high-risk leukemia patients 3Health News:Early-stage melanoma tumors contain clues to metastatic potential 2Health News:Early-stage melanoma tumors contain clues to metastatic potential 3Health News:Novel combined therapy extends life, diminishes pain in brain cancer patients 2Health News:Training in Positive Thinking May Help Anxious Teens 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: